DMED.CN - Diagnamed Holdings Corp.
| Previous Close | 0.0550 |
| Open | 0.0550 |
| Bid | 0.0500 x N/A |
| Ask | 0.0600 x N/A |
| Day's Range | 0.0500 - 0.0600 |
| 52 Week Range | 0.0200 - 0.1150 |
| Volume | |
| Avg. Volume | 241,746 |
| Market Cap | 4.585M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireDiagnaMed Launches PalGPT.ai, a Generative AI Brain Health Solution
TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is pleased to announce the launch of PalGPT.ai (https://palgpt.ai), a generative AI brain health solution powered by OpenAI's ChatGPT for people seeking an AI companion to have meaningful private conversations, friendly advice and share inner thoughts. PalGPT.ai is the Company’s second commercial product from its Health GenAI
- GlobeNewswire
DiagnaMed Announces DTC Eligibility of Its Common Shares in the United States
TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is pleased to announce that its OTCQB-listed common shares under the symbol “DGNMF” are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States. DTC Eligibility is expected to simplify the process of trading and enhance liquidity of DiagnaMed’s common shares in the
- GlobeNewswire
DiagnaMed Launches “Health GenAI”, a New Division for Generative AI Healthcare Solutions
Focused on Health GenAI and CERVAI™, a generative AI brain health platformTORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is pleased to announce the launch of Health GenAI, a new division focused on the development and commercialization of a suite of generative AI ready-made and customizable applications powered by GPT-4 to support the healthcare market in improving patient
- GlobeNewswire
DiagnaMed Launches FormGPT.io, a Generative AI Healthcare Solution
TORONTO, May 03, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is pleased to announce the launch of FormGPT.io, a generative AI data collection and analysis solution for the healthcare market. FormGPT.io (www.FormGPT.io) is the first commercial product by the Company as part of its initiative to launch a suite of generative AI ready-made and customizable applications powered by GPT-4 to s
- GlobeNewswire
DiagnaMed Announces Listing on OTCQB in the United States
TORONTO, April 11, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health AI company, is pleased to announce that effective April 11, 2023, the Company is listed on the OTCQB Venture Market (“OTCQB”) under the symbol “DGNMF”. The Company will continue to trade on the Canadian Securities Exchange (“CSE”) under its existing symbol “DMED”. The Company has also applied to the Depository Trust Company (“DTC”) for DTC eligibility,
- GlobeNewswire
DiagnaMed Announces Dr. Bassma Ghali as Vice President of Product
Former Reliq Health Technologies Chief Innovation Officer and veteran product leader brings over a decade of experience building and commercializing digital health products to DiagnaMedTORONTO, March 22, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health AI company, is pleased to announce the addition of Dr. Bassma Ghali, Ph.D., P.Eng., as its new Vice President of Product. Previously, Dr. Ghali was the Chief Innovation Officer of Reliq
- GlobeNewswire
DiagnaMed Announces Application for OTCQB Listing
Increasing awareness within the U.S. capital markets DiagnaMed focused on commercializing CERVAI™, its proprietary Brain Health AI Platform leveraging Generative AI TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health AI company, is pleased to announce that it has applied for uplisting of its common shares to be trading on the OTCQB® Venture Market (“OTCQB”). The Company will continue to trade on the Canadian Securities
- GlobeNewswire
DiagnaMed Enters into License Agreement with University of Miami for Brain Health Platform for Integration with CERVAI™, a Brain Health AI Platform Leveraging Generative AI
TORONTO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, is pleased to announce that it has entered into a license agreement with the University of Miami (“UM”) for the development and commercialization of intellectual property of a novel brain health platform for the evaluation, diagnosis and monitoring of brain health, such as Alzheimer's disease and related dementias (“ADRD”), which will be incorpor
- GlobeNewswire
DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI
CERVAI™ to be available in May 2023TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, today announces that it is prioritizing resources to solely focus on the development and commercialization of CERVAI™, a proprietary Brain Health Artificial Intelligence (“AI”) Platform leveraging Generative AI. CERVAI™ aims to predict and monitor brain age and provide actionable insights and tools to diagnose,
- GlobeNewswire
DiagnaMed Announces Appointment of New Director
TORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, announced today that Ms. Emily Davis resigned as director of the Board of Directors (the “Board”) and is replaced by the appointment of Mr. Carlo Sansalone to the Board as independent non-executive director, effective immediately. Mr. Sansalone has over 10 years’ experience with private and public companies, including senior management positions
- GlobeNewswire
DiagnaMed Holdings Incorporates OpenAI’s ChatGPT into BRAIN AGE™ AI Product Suite
Brain Health Digital Platform to be available in May 2023TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), an artificial intelligence-driven digital health company focusing on improving brain health, today announces that it will incorporate OpenAI’s technology, ChatGPT, in its BRAIN AGE™ Artificial Intelligence (“AI”) Product Suite, which already includes a variety of API interfaces to build AI and machine learning functions, to furth
- GlobeNewswire
DiagnaMed Holdings Provides Update for BRAIN AGE™ Development and Commercialization Milestones for 2023
Complete IRB-approved research study in Q2-2023 Commercialize BRAIN AGE™ in Q4-2023 TORONTO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), an artificial intelligence-driven digital health company focusing on improving brain health, today provided an update on its development and commercialization plans and expected milestones in 2023 for BRAIN AGE™, a proprietary electroencephalogram-based (“EEG”) artificial intelligence solution to detect
GlobeNewswireDiagnaMed Holdings Acquires Exclusive Rights to a Virtual Reality and Artificial Intelligence-based Neurodiagnostic System for Neurodegenerative Disease
Prototype of the VR/AI Neuro System Prototype of the VR/AI Neuro System Exclusive license of intellectual property from the University of Kansas of a proprietary diagnostic tool combining artificial intelligence and virtual reality to assist in the diagnosis of neurological disorders for clinical and telemedicine use Enables remote neurological diagnosis on a low-cost, portable virtual reality device that can visualize eye movements in videos and interface with the physician who is in a differen